LENZ has announced an exclusive licensing and commercialisation agreement with Lotus Pharmaceutical of Taiwan.

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

ARVO presentation highlights 12-month results from Phase 1/2 study that support potential of OPGx-LCA5 gene therapy to ...

LENZ Therapeutics, Inc.’s LENZ share price has dipped by 5.70%, which has investors questioning if this is right time to buy.

The World Health Organization (WHO) has partnered with the Universal Postal Union (UPU) to expand access to eye care using ...

EXPLORE Health Money Travel Food Style Book Club Classifieds #ZoomerDaily Policy & Perspective Arts & Entertainment Stars & ...

Presbyopia is caused by a stiffening in the lens of the eye that develops in people after the age of 40, and affects an estimated 128 million people in the US. AbbVie is recommending Vuity ...

Corneal allogenic intrastromal ring segments, or CAIRS, have been gaining momentum over the years as a minimally invasive ...

Janardhan, Specialist Ophthalmology at Aster Clinic, Karama (UMC) says, “Regular eye check-ups aren’t just about getting a ...

Bausch + Lomb has made more than 6000 parameters available in the Ultra Multifocal for Astigmatism product. OT learnt more at ...

The FDA has approved the first and so far only pharmacological treatment for presbyopia, a sight condition that typically starts in middle age and involves difficulty in focusing on near objects ...